If you’ve spent any time in cat owner communities lately, you’ve probably seen the question circulating: will there ever be an Ozempic for cats? As of June 2026, the answer is closer than most people realize, and it’s worth understanding what’s actually being tested before the hype machine gets fully revved up.

OKAVA Pharmaceuticals launched the MEOW-1 trial in late 2025, the first GLP-1 weight-loss clinical study ever conducted in cats or dogs. Results are expected this summer. New data was just presented at the 2026 ACVIM Forum in Seattle, and veterinary endocrinologists are paying attention. If you have an overweight cat, this is the moment to get informed, not after your vet asks you whether you’ve heard about it.

What OKV-119 Actually Is (and Isn’t)

Most coverage frames this as “Ozempic for cats,” which is technically imprecise and practically misleading. OKV-119 isn’t a weekly injection your cat gets at home. It’s a tiny subcutaneous implant, inserted at a single vet visit, that releases exenatide steadily for up to six months.

Exenatide matters here. It was the first FDA-approved GLP-1 agonist, cleared for human type 2 diabetes in 2005, which means there are two decades of human safety data behind the molecule. OKAVA isn’t experimenting with a novel compound. They’re delivering an established drug through a novel delivery system designed specifically for the realities of cat ownership, which is to say, the reality that most cats will not tolerate weekly injections at home without turning the whole household into a trauma response.

The implant approach is genuinely clever. Steady-state drug release avoids the peaks and troughs of intermittent dosing. It removes owner compliance as a variable. And one vet visit every six months is manageable in a way that weekly injections simply aren’t for most households. Whether it works is what MEOW-1 is designed to determine.

Why Feline Obesity Is a Bigger Problem Than Most Owners Admit

Recommended Vet-Approved Dog First Aid Kit with Tick Remover

Essential pet emergency kit with first aid guide, slip leash, and medical supplies for home, car, and camping.

Check Price →

Helpful resource: Midwest Homes Folding Metal Dog Crate is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)

More than half of U.S. cats are classified as overweight or obese, according to the Association for Pet Obesity Prevention. That’s not a “chunky cat” aesthetic situation. Excess weight in cats is directly linked to type 2 diabetes, hepatic lipidosis, osteoarthritis, and a shortened lifespan. The number of overweight cats has been climbing for years, and the standard veterinary prescription of “feed less, play more” has a poor track record in practice.

The problem isn’t owner laziness. Cats are extraordinarily good at demanding food, and the relationship between a cat and its owner often runs through the food bowl. Cats also have specific metabolic quirks: they’re obligate carnivores with different insulin dynamics than dogs or humans, which is part of why veterinary researchers have been cautious about extrapolating human GLP-1 data directly to feline patients. GLP-1 receptors exist in cats, but their distribution and behavior aren’t identical to humans, and appetite regulation in cats involves additional pathways that aren’t fully mapped. The MEOW-1 trial is generating the species-specific data that has simply never existed before.

What’s Happening Right Now in Clinical Practice

Here’s what most articles leave out: GLP-1 drugs are already being used in cats, just not for weight loss. Some veterinary endocrinologists use human GLP-1 medications off-label in diabetic cats. A Texas A&M specialist told the New York Times he uses them a handful of times a year. That’s specialist territory, not something happening at your general practice, but it confirms that the drugs aren’t completely uncharted in feline medicine.

The gap between “a handful of diabetic cats seen by a specialist” and “an FDA-approved weight-loss implant available at your regular vet” is significant. It involves completed trial data, regulatory review, manufacturing, and veterinary training. None of that happens overnight. Even if MEOW-1 results are positive this summer, a commercially available product is still years away. According to Smithsonian Magazine’s December 2025 coverage of the trial launch, OKAVA is also developing a dog version of the implant, which signals they’re building toward a broader platform, not a single product.

The commercial sector is already moving in parallel. Better Choice Company announced in early 2025 that it plans to invest up to $1.5 million developing a GLP-1 pet treat. The science behind a treat-delivered GLP-1 is considerably more complicated than a subcutaneous implant, given bioavailability and dosing control issues, but the investment signals how seriously the pet industry is taking the obesity problem.

What Cat Owners Should Actually Do Right Now

Nothing about this trial changes your cat’s care today. But a few things are worth doing while this field develops.

Get an honest body condition score at your next vet visit, not a vague “he could stand to lose a few pounds” comment, but an actual 1-9 scale score documented in the chart. That baseline matters if you’re ever going to track progress or have a meaningful conversation about medical intervention.

Ask your vet whether they’re following the GLP-1 research in pets. Their answer tells you something useful. A vet who’s aware of the MEOW-1 trial and the ACVIM Forum data is a vet who will be able to advise you thoughtfully when options do become available. A vet who’s never heard of it isn’t necessarily behind, but it’s worth knowing.

Don’t ask your vet to prescribe human semaglutide or tirzepatide for your cat. The off-label use that does exist in feline medicine is exenatide in diabetic cats under specialist supervision, not weight-loss dosing of drugs optimized for human metabolic profiles. The risks of inappropriate GLP-1 use in cats, including hypoglycemia, nausea, muscle wasting, and pancreatitis, are real. This is not a DIY situation.

As Futurism reported in December 2025, the researchers behind these trials are explicit that species-specific safety data is the whole point of doing controlled trials rather than assuming human data transfers cleanly. That caution is correct.

When Results Drop, Here’s How to Read Them

MEOW-1 results are expected sometime this summer. When coverage hits, look for a few specific things before getting excited or dismissing the findings. What was the percentage of body weight lost, and over what time period? What adverse events were reported and at what frequency? Was there a control group, and how were cats selected? What happened to blood glucose and lean muscle mass, not just total weight?

Weight loss in cats can be dangerous if it happens too fast or comes from muscle rather than fat. A drug that produces rapid total weight loss in cats without adequate lean mass preservation would be a serious problem, not a success. Good results here mean steady fat loss, maintained muscle, and a clean safety profile. That’s the bar.

The veterinary field is genuinely excited about this area of research, and for good reason. Obesity is the most common preventable disease in companion animals, and diet and exercise counseling alone hasn’t moved the needle. But excitement doesn’t substitute for data, and your overweight cat deserves decisions made on evidence rather than headlines.

The summer results will tell us whether OKV-119 actually works. Until then, the most useful thing you can do is keep your cat’s weight documented, stay curious, and resist the urge to improvise with human medications. The science is moving. Let it finish.

Sources

This article is for general informational purposes only and does not constitute veterinary advice. Pet health symptoms can have many causes and require professional evaluation. Always consult a licensed veterinarian for diagnosis and treatment specific to your pet.

Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.